Maine Dual-License Cannabis 280E: Schedule III Apportionment Guide

Overview

For the first time since IRC Section 280E was enacted in 1982, the federal tax treatment of state-licensed medical cannabis is in real flux. On April 28, 2026, the U.S. Department of Justice issued a Final Order placing marijuana subject to a state medical marijuana license in Schedule III of the Controlled Substances Act. For Maine operators who hold both a medical license (caregiver storefront, registered caregiver, or licensed medical dispensary) and an adult-use license from the Office of Cannabis Policy, the change creates an immediate, documentable tax-planning opportunity — and an immediate compliance obligation.

This guide is written for the operator, controller, or outside CPA who has a dual-license Maine cannabis business and needs to understand: (1) what the April 28 order actually changed, (2) what is still on Schedule I and still subject to 280E, (3) how to apportion shared expenses between the two license types, (4) the June 27, 2026 expedited DEA registration deadline, and (5) how the broader June 29 – July 15 DEA rescheduling hearing could shift the answer again. This is technical B2B content; the goal is to give you the framework your tax advisor will need to act on the new law.

What the April 28, 2026 Final Order Actually Did

The Acting Attorney General's authority to place drugs in Schedule III derives from Section 811(d)(1) of the Controlled Substances Act, which Congress enacted to let the executive branch bring domestic scheduling into compliance with the 1961 Single Convention on Narcotic Drugs without a full notice-and-comment rulemaking. The April 23, 2026 announcement and the April 28, 2026 Federal Register publication together moved two distinct categories of marijuana to Schedule III:

1. Marijuana in an FDA-approved drug product — currently a narrow set (the only FDA-approved cannabis-derived product is Epidiolex and a handful of Marinol-class synthetics). This category does not directly affect Maine operators.
2. Marijuana subject to a state-issued medical marijuana license — this is the operative category for Maine. A "state medical marijuana license" under the order is read broadly: it includes caregivers, caregiver storefronts, medical dispensaries, and any other entity registered with the Maine Office of Cannabis Policy to manufacture, distribute, or dispense cannabis for medical use.

For tax purposes, the operative consequence is that 280E — which by its terms applies to trafficking in Schedule I or Schedule II controlled substances — no longer attaches to income and expenses from the Schedule III medical side. The IRS does not have authority to disallow ordinary business deductions on income from a substance that is not Schedule I or II. Standard Section 162 deductions (rent, payroll, marketing, software, insurance, professional fees) are once again available for the medical books.

The order also opened a new expedited DEA registration pathway under 21 CFR Part 1301. State medical licensees can apply for DEA registration as manufacturers, distributors, and/or dispensers. Applicants who file within 60 days of publication — by June 27, 2026 — receive priority six-month review and may continue operating under their state-issued license during the application pendency. After the 60-day window, applications are processed under the standard pathway with no statutory bridge from state to federal authority.

What Did Not Change

Three things are important not to overread:

• Adult-use is still Schedule I. The April 28 order does not move recreational marijuana. The 280E trap is still fully closed around your adult-use books until the broader rescheduling concludes. Maine's combined medical + adult-use market is the only one in the country where medical out-weighs adult-use ($280M vs. $217M in 2023 per the OCP 2025 annual report), which is why the dual-license apportionment problem is uniquely large here.
• Bankruptcy and tax collections are still federally restricted. IRC Section 280E removes ordinary deductions; the underlying federal illegality under the Controlled Substances Act for Schedule I substances continues to create banking, R&D credit, and bankruptcy hurdles for the adult-use side.
• State tax treatment is unchanged. Maine has permitted ordinary business deductions on state returns since 2018 (24 M.R.S. §5122, the "income subtraction modification"). You were already getting the deduction on the state side; the April 28 order unlocks the federal side for the medical component only.

The Apportionment Framework

For a dual-license operator, the question is no longer "is any of this deductible?" — it is "how do I split shared overhead between the medical books, which are now 162-eligible, and the adult-use books, which are still 280E-trapped?" The federal case law, IRS guidance, and Maine practice all support a documented, consistently-applied allocation methodology. The four that matter:

1. Revenue Allocation

Allocating shared expenses by the revenue share of each license type is the simplest and most common methodology. If your medical channel is 35% of total revenue for the period, 35% of shared overhead is allocated to the medical side. Strength: easy to compute, easy to defend. Weakness: revenue mix can shift seasonally, so a single annual ratio may not match the period you are trying to allocate.

2. Square Footage Allocation

Allocating rent, utilities, and facility overhead by the square footage dedicated to medical vs. adult-use activity is the cleanest methodology where the operations are physically separate. A common implementation: a separate dispensary room for medical patients, a separate check-in desk, separate inventory storage. Strength: audit-defensible. Weakness: a single shared back office, shared HVAC, and shared point-of-sale hardware can blur the lines.

3. Employee Time Allocation

Allocating payroll, benefits, and training by employee-reported time across the two channels. Strength: most accurate for labor. Weakness: requires time-tracking discipline, which most small operators do not have; an estimate methodology with annual reconciliation is acceptable if consistently applied.

4. Headcount or Transaction Count

Allocating POS-related overhead, customer acquisition cost, and loyalty program expense by the number of transactions (or unique patients/customers) in each channel. Strength: clean for marketing and POS-software expenses. Weakness: not appropriate for rent or insurance.

Most Maine dual-license operators use a blended methodology: square footage for facility overhead, employee time for payroll, revenue share for everything else. The methodology must be in writing, signed by a controller or CPA, applied consistently across all reporting periods, and updated when operations change materially. A methodology that changes year to year without explanation is the audit trigger that produces the worst-case outcome.

The June 27, 2026 Deadline You Cannot Miss

The expedited DEA registration window opened with Federal Register publication on April 28, 2026, and closes 60 days later — June 27, 2026. Operators who file their 21 CFR Part 1301 application within the window receive:

• Priority six-month review. DEA is directed by the Final Order to process all 60-day applications within six months.
• Statutory authority to operate under the state-issued license during the application pendency. New 21 CFR 1301.13(k) explicitly allows applicants who file within 60 days to engage in manufacture, distribution, and dispensing in conformity with the state license while DEA reviews.
• A federal registration that survives suspension of the underlying state license. The order provides that federal registration automatically suspends if the state license is suspended, revoked, or expires — meaning the federal authorization tracks state authorization rather than replacing it.

For a dual-license operator with a Schedule III medical component, filing within the window is essentially a no-regret action. The application is straightforward (state license, fingerprints, $244 three-year registration fee for a dispenser, similar to a standard DEA practitioner registration). The downside of missing it is small — standard applications are still accepted — but the upside of having a priority-track federal registration and the statutory bridge during review is large, particularly if you handle products at the FDA-approved boundary or sell across state lines.

Watching the June 29 – July 15 Rescheduling Hearing

Separately, the DEA will hold a formal administrative hearing beginning June 29, 2026 at the DEA Hearing Facility in Arlington, Virginia, on the proposed rule to transfer all marijuana from Schedule I to Schedule III. The hearing must conclude no later than July 15, 2026. The Acting Attorney General designated an Administrative Law Judge on June 22, 2026, and the hearing was originally scheduled to begin December 2, 2024 before being withdrawn and restarted under the December 18, 2025 Executive Order 14370.

What the hearing can produce: a recommended decision from the ALJ, a final DEA order, and eventually a Federal Register publication that moves adult-use cannabis to Schedule III. What the hearing cannot produce on its own: a Schedule III designation for adult-use. That requires a final rule. The realistic timeline from hearing conclusion to a final rule ranges from late 2026 (if the ALJ issues a clean recommended decision and the DEA adopts it) to 2027 or 2028 (if there are post-hearing comments, additional proceedings, or a challenge).

For dual-license operators, the strategic question is: do you build a tax structure that works if adult-use is still Schedule I in 2027, or do you pre-build for the post-rescheduling world? The right answer is the former. The April 28 medical-only Schedule III order is locked in and unambiguous; the broader rescheduling is a conditional that may or may not land on your planning horizon. Build for the schedule you have, not the schedule you hope for.

Action Items for Maine Dual-License Operators

Key Takeaways

• The April 28, 2026 DOJ Final Order moved state-licensed medical marijuana to Schedule III. For Maine dual-license operators, ordinary Section 162 business deductions are now available for the medical component of operations.
• Adult-use remains on Schedule I. The 280E trap is still fully closed around your adult-use books. The Schedule III reclassification does not solve the adult-use problem; it solves the medical-side problem only.
• The dual-license apportionment framework — square footage for facility, employee time for labor, revenue share for everything else — is the cleanest implementation. The methodology must be in writing and applied consistently.
• The expedited DEA registration window closes June 27, 2026. Filing within 60 days gets priority review and statutory authority to operate under your state license during processing.
• The June 29 – July 15, 2026 DEA rescheduling hearing is procedural. Do not pre-build a tax structure on the assumption that adult-use moves to Schedule III in 2026.